New CMS Accountable Care Model Expected to Benefit Value-Based Care Providers
New ACO Model Introduction: CMS has announced the Long-term Enhanced ACO Design (LEAD) model, a 10-year voluntary pilot program starting in 2027, aimed at improving value-based care for healthcare providers.
Improvements Over Previous Model: LEAD addresses financial and administrative challenges faced by providers, offering enhanced cash flow payments and tools to better meet patient needs, particularly for high-needs patients.
Positive Industry Reaction: Jefferies has responded favorably to the LEAD model, indicating it provides future flexibility and stability for value-based care within Medicare fee-for-service.
Supporting Companies: Companies like Astrana Health, agilon health, and Privia Health Group are involved in supporting ACOs, with recent developments in their financial standings and market positions.
Trade with 70% Backtested Accuracy
Analyst Views on AGL
About AGL
About the author

- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Agilon Health, Inc., involving investors who purchased securities between February 26, 2025, and August 4, 2025, alleging that the company made false or misleading statements during this period, resulting in investor losses.
- Allegation Details: The lawsuit claims that Agilon executives knowingly issued unattainable financial guidance amidst significant industry challenges and overstated the immediate financial impact of their 'strategic actions,' leading to materially false perceptions of the company's business and prospects among investors.
- Investor Rights: Affected investors must apply by March 2, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for more information.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, boasting extensive litigation experience and a nationwide practice.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, to represent other investors in the class action lawsuit.
- Potential Compensation Opportunity: Participants may receive compensation through a contingency fee arrangement without upfront costs, indicating that the lawsuit offers legal support to investors without additional financial burden, potentially attracting more affected investors.
- Lawsuit Background: The lawsuit alleges that Agilon Health made misleading financial guidance during the class period, resulting in investor losses once the true details were revealed, highlighting management failures in addressing industry challenges.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health and certain officers, alleging violations of federal securities laws on behalf of investors who purchased Agilon securities between February 26, 2025, and August 4, 2025, seeking damages for affected parties.
- False Statement Allegations: The complaint claims that throughout the class period, defendants made false and/or misleading statements and failed to disclose significant industry headwinds that would prevent them from achieving their 2026 financial guidance, misleading investors about the company's prospects.
- Exaggerated Financial Impact: Defendants are accused of materially overstating the immediate positive financial impact of strategic actions taken by Agilon, resulting in materially false and/or misleading statements regarding the company's operations and future outlook at all times.
- Investor Action Recommendation: Affected investors have until March 2, 2026, to request to be appointed as lead plaintiff, allowing them to participate in any potential recovery, with the lawsuit not requiring them to serve as lead plaintiff to share in any recovery.
- Investor Rights Protection: Faruq & Faruqi LLP is investigating potential claims against agilon health, particularly for investors who purchased securities between February 26, 2025, and August 4, 2025, aiming to safeguard investor legal rights.
- Litigation Deadline Reminder: The firm reminds investors that March 2, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, necessitating timely action from investors to protect their interests.
- Legal Consultation Channels: Investors who have suffered losses can directly contact Faruqi & Faruqi partner Josh Wilson, with multiple contact options provided to facilitate investor inquiries and ensure they receive necessary legal support.
- Market Impact: This investigation may negatively affect agilon health's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Agilon Health made false and misleading statements during the class period, resulting in investor losses when the true information became public, indicating significant misjudgments in the company's financial outlook.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling such cases.
- Lawsuit Background: Levi & Korsinsky LLP has notified investors that Agilon Health, Inc. (NYSE: AGL) is facing a class action lawsuit for alleged securities fraud, covering the period from February 26, 2025, to August 4, 2025, aimed at recovering losses for affected investors.
- False Statement Allegations: The complaint alleges that the defendants recklessly issued guidance for 2025 without disclosing significant industry headwinds, resulting in materially false and misleading statements regarding the company's business and prospects.
- Investor Rights: Affected investors have until March 2, 2026, to request to be appointed as lead plaintiff to participate in potential recovery, with no out-of-pocket costs or obligations required, thus lowering the barrier for investor participation.
- Law Firm Expertise: With 20 years of experience in securities litigation, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years, showcasing its expertise in complex securities cases.











